Skip to content
CampeloLabs

Blog

Practical AI guides for founders

Short, useful reads on growing your startup with AI, safely. From the team behind AI Operating System for Startups. See also AI startups from Y Combinator.

A designer directing a coding agent through many one-shot website iterations, pinning the few worth keeping while hand-drawing the one piece of art left entirely to human craft

August 9, 2026 · 14 min read

AI for Designers: The YC Design Workflow

Search for AI for designers and page one hands you a tool list. A tool list does not tell you what actually changes in the work. Y Combinator's Head of Design does: she barely opens a static design file, does not type at all, and builds throwaway tools for herself in the middle of a project. The interesting part is not the automation. It is what she feeds the agent before she prompts it, and which parts of the job she deliberately left untouched.

Read more →
A founder replacing a chain of separate fraud review stages, a rules engine, a classifier, and a human analyst queue, with a single agent that closes the investigation loop

August 8, 2026 · 13 min read

AI Fraud Detection: Build the Feedback Loop

Page one for this query is a wall of vendor explainers telling you that machine learning finds anomalies faster than people do. True, and useless. It does not tell a founder what to build or why the fraud stack most companies run today cannot keep up with the people attacking it. A company that spent three years reviewing GoFundMe fundraisers and verifying sellers for a Fortune 50, without naming most of its customers, gives a much better answer, and it turns on feedback loops rather than model quality.

Read more →
A founder weighing synthetic users against real customer interviews, comparing a large grid of simulated profiles with a small set of recorded conversations to decide which questions to trust to the simulation

August 7, 2026 · 16 min read

Synthetic Users: When to Trust the Simulation

Synthetic users are AI stand-ins for real customers: ask a thousand of them a question and get a distribution back in minutes instead of a fielded study in six weeks. The category is now funded like it works, and the most useful guide to it comes from the researcher who built it, because he spends most of his time explaining what it cannot do. Here is the test that decides which questions a simulation can answer, what the accuracy figures really mean, and where synthetic users still break.

Read more →
A founder sorting a startup roadmap against an AGI timeline, separating bets that improve if a more capable model arrives mid-build from bets that do not

August 6, 2026 · 17 min read

AGI Timeline: What Founders Should Build Now

The AGI timeline quoted most often is around 2030. Demis Hassabis says it on stage at Y Combinator, and François Chollet, who built a benchmark specifically to show that scaling alone is not enough, lands on almost the same year by the opposite reasoning. What they do not share is a definition, which is why the date is the least useful thing in the forecast. Here is the planning rule Hassabis actually gives founders, the markers worth tracking instead of the year, and how to sort a roadmap into bets that get better if he is right and bets that die.

Read more →
Context rot in practice: a founder watching a long AI agent session degrade, choosing between clearing the context and delegating the work to a fresh sub-agent

August 5, 2026 · 17 min read

Context Rot: What It Is and How to Catch It

Context rot is what happens to a coding agent session that starts brilliant and turns by hour three: the agent confidently rewrites code it already wrote, fixated on something that was never true. That failure has names now: context rot, context poisoning, and the dumb zone. They are not the same thing, and the fix is different for each. Here is how to tell them apart, how to catch the failure before it costs you a day, and what the people who built these agents actually do when it happens.

Read more →
AI drug discovery tradeoff: a founder standing between a wall of predicted molecular structures and a working laboratory bench, weighing which one to invest in

August 4, 2026 · 18 min read

AI Drug Discovery: Where the Real Moat Is

AI drug discovery has a pair of numbers that decides everything: AI-discovered molecules clear Phase I trials 80 to 90 percent of the time, well above the historic industry average. In Phase II, the number drops to roughly 40 percent, which is exactly where the industry has always been. AI has gotten good at designing something that behaves like a drug, and has not yet moved the number that decides whether you have a company. For a founder, it means the defensible asset was never the model.

Read more →